Genmab — Februar 2020
-
Heller ikke morsomt i mine porteføljer.
-
Long-term follow-up from POLLUX | Daratumumab in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.https://multiplemyelomahub.com/medical-information/long-term-follow-up-from-pollux-daratumumab-in-combination-with-lenalidomide-and-dexamethasone-for-relapsed-or-refractory-multiple-myeloma
-
Conclusion2
DRd significantly prolonged PFS compared to Rd in all patient subgroups, while demonstrating a 56% reduction in the risk of disease progression or death at the 3.5-year follow-up. The greatest clinical benefit of DRd was observed in patients that had received one prior line of therapy, supporting the use of DRd in patients with RRMM after first relapse. The safety profile of DRd remains as described in the 2018 analysis with no additional concerns, and DRd continues to produce favor
-
able clinical outcomes in patients with RRMM.
-
Om få uger kan vi se de første kliniske resultater på en Corona vaccine https://www.france24.com/en/20200228-who-upgrades-global-risk-of-coronavirus-spread-to-maximum-level
-
Morn
Active Corona faldet til 42779 - https://www.worldometers.info/coronavirus/ -
God morgen.
-
Blood -
A prospective phase II of daratumumab in previously treated systemic light chain amyloidosis (AL) patients - https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2019004369/452572/A-prospective-phase-II-of-daratumumab-in?redirectedFrom=fulltext
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind